Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GSK’s Diabetes Drug Tanzeum Gains FDA Approval | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

GSK’s Diabetes Drug Tanzeum Gains FDA Approval

Employs Novozymes' VELTIS technology for optimized dosing

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

The FDA has approved GlaxoSmithKline’s new type 2 diabetes drug Tanzeum that employs Novozymes’ Veltis technology to achieve an extended half-life requiring once a week administration. The drug has also recently been approved in Europe as the brand Eperzan.
 
Novozymes’ VELTIS technology represents a series of engineered human albumins that in combination with a drug candidate, offers the potential for control of the therapeutic half-life, which allows for reducing the dosing frequency of drugs from daily to every two weeks or monthly.
 
“This is yet another important market approval for a drug based on Novozymes’ Veltis technology,” said Dermot Pearson, marketing director, Novozymes Biopharma. “The versatile capabilities of our solution are being continually demonstrated by our customers. Not only has Novozymes developed a platform that helps medicines achieve optimum therapeutic effect, but that also improves the day-to-day management of conditions by extending drug half-life and, therefore, reducing the frequency at which patients need to inject.”
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics